Literature DB >> 20189880

Testing the amyloid hypothesis of Alzheimer's disease in vivo.

Sam Gandy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20189880      PMCID： PMC3274723          DOI： 10.1016/S1474-4422(10)70055-7

Source DB:  PubMed          Journal:  Lancet Neurol        ISSN： 1474-4422            Impact factor:   44.182


× No keyword cloud information.
  12 in total

1.  Hindering of proteinopathy-induced neurodegeneration as a new mechanism of action for neuroprotectors and cognition enhancing compounds.

Authors:  S O Bachurin; A A Ustyugov; O Peters; T A Shelkovnikova; V L Buchman; N N Ninkina
Journal:  Dokl Biochem Biophys       Date:  2009 Sep-Oct       Impact factor: 0.788

Review 2.  Sorting through the cell biology of Alzheimer's disease: intracellular pathways to pathogenesis.

Authors:  Scott A Small; Sam Gandy
Journal:  Neuron       Date:  2006-10-05       Impact factor: 17.173

3.  Homotaurine: a failed drug for Alzheimer's disease and now a nutraceutical for memory protection.

Authors:  Michael T Swanoski
Journal:  Am J Health Syst Pharm       Date:  2009-11-01       Impact factor: 2.637

4.  11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study.

Authors:  Juha O Rinne; David J Brooks; Martin N Rossor; Nick C Fox; Roger Bullock; William E Klunk; Chester A Mathis; Kaj Blennow; Jerome Barakos; Aren A Okello; Sofia Rodriguez Martinez de Liano; Enchi Liu; Martin Koller; Keith M Gregg; Dale Schenk; Ronald Black; Michael Grundman
Journal:  Lancet Neurol       Date:  2010-02-26       Impact factor: 44.182

5.  Abeta species removal after abeta42 immunization.

Authors:  James A R Nicoll; Edward Barton; Delphine Boche; Jim W Neal; Isidro Ferrer; Petrina Thompson; Christina Vlachouli; David Wilkinson; Antony Bayer; Dora Games; Peter Seubert; Dale Schenk; Clive Holmes
Journal:  J Neuropathol Exp Neurol       Date:  2006-11       Impact factor: 3.685

6.  Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.

Authors:  Robert C Green; Lon S Schneider; David A Amato; Andrew P Beelen; Gordon Wilcock; Edward A Swabb; Kenton H Zavitz
Journal:  JAMA       Date:  2009-12-16       Impact factor: 56.272

7.  A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease.

Authors:  S Salloway; R Sperling; S Gilman; N C Fox; K Blennow; M Raskind; M Sabbagh; L S Honig; R Doody; C H van Dyck; R Mulnard; J Barakos; K M Gregg; E Liu; I Lieberburg; D Schenk; R Black; M Grundman
Journal:  Neurology       Date:  2009-11-18       Impact factor: 9.910

Review 8.  Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea.

Authors:  Marwan N Sabbagh; Holly A Shill
Journal:  Curr Opin Investig Drugs       Date:  2010-01

Review 9.  Amyloid-beta oligomers: possible roles as key neurotoxins in Alzheimer's Disease.

Authors:  Alex L Lublin; Sam Gandy
Journal:  Mt Sinai J Med       Date:  2010 Jan-Feb

10.  Acute dosing of latrepirdine (Dimebon), a possible Alzheimer therapeutic, elevates extracellular amyloid-beta levels in vitro and in vivo.

Authors:  John W Steele; Soong H Kim; John R Cirrito; Deborah K Verges; Jessica L Restivo; David Westaway; Paul Fraser; Peter St George Hyslop; Mary Sano; Ilya Bezprozvanny; Michelle E Ehrlich; David M Holtzman; Sam Gandy
Journal:  Mol Neurodegener       Date:  2009-12-17       Impact factor: 14.195
View more
  6 in total

Review 1.  Transcranial near-infrared laser therapy applied to promote clinical recovery in acute and chronic neurodegenerative diseases.

Authors:  Paul A Lapchak
Journal:  Expert Rev Med Devices       Date:  2012-01       Impact factor: 3.166

2.  New pathway links γ-secretase to inflammation and memory while sparing notch.

Authors:  Sam Gandy; Brandon Wustman
Journal:  Ann Neurol       Date:  2011-01       Impact factor: 10.422

3.  A monoclonal antibody against synthetic Aβ dimer assemblies neutralizes brain-derived synaptic plasticity-disrupting Aβ.

Authors:  Brian O'Nuallain; Igor Klyubin; Jessica M Mc Donald; James S Foster; Alfred Welzel; Andrew Barry; Richard K Dykoski; James P Cleary; Martijn F B G Gebbink; Michael J Rowan; Dominic M Walsh
Journal:  J Neurochem       Date:  2011-08-22       Impact factor: 5.372

4.  Neutralization of soluble, synaptotoxic amyloid β species by antibodies is epitope specific.

Authors:  Wagner Zago; Manuel Buttini; Thomas A Comery; Christopher Nishioka; Shyra J Gardai; Peter Seubert; Dora Games; Frédérique Bard; Dale Schenk; Gene G Kinney
Journal:  J Neurosci       Date:  2012-02-22       Impact factor: 6.167

Review 5.  Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress.

Authors:  Sam Gandy; Steven T DeKosky
Journal:  Annu Rev Med       Date:  2013       Impact factor: 13.739

6.  Human anti-Aβ IgGs target conformational epitopes on synthetic dimer assemblies and the AD brain-derived peptide.

Authors:  Alfred T Welzel; Angela D Williams; Helen P McWilliams-Koeppen; Luis Acero; Alfred Weber; Veronika Blinder; Alex Mably; Sebastian Bunk; Corinna Hermann; Michael A Farrell; Hartmut J Ehrlich; Hans P Schwarz; Dominic M Walsh; Alan Solomon; Brian O'Nuallain
Journal:  PLoS One       Date:  2012-11-27       Impact factor: 3.240
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.